ArticleBMC bioinformatics2026
CMV-GLA: contrastive multi-view graph layer attention for predicting phosphorylation site-disease associations.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Protein phosphorylation is a critical posttranslational modification involved in cell signaling and metabolic regulation, and phosphorylation dysregulation is closely associated with various diseases. However, studies on phosphorylation site-disease associations remain scarce, and existing methods often fail to fully leverage complementary information across heterogeneous data sources, resulting in suboptimal predictive performance. We present CMV-GLA (Contrastive Multi-View Graph Layer Attention Network), a novel framework integrating protein sequences, disease semantics, and known associations into three complementary graph views (site similarity, disease similarity, association network). Built on a GAT backbone, CMV-GLA employs layer attention to mitigate over-smoothing and contrastive learning to maximize cross-view node embedding consistency while minimizing inter-node confusion, enhancing discriminative power. Specifically, the contrastive learning module encourages consistent representations of the same node across different graph views while explicitly separating embeddings of unrelated nodes, leading to more distinguishable and robust feature representations. Evaluated on benchmark data, CMV-GLA significantly outperforms state-of-the-art methods in AUC and AUPRC. Ablation studies confirm the critical roles of multi-view fusion and the contrastive module. Case studies demonstrate high-confidence, literature-supported predictions, highlighting CMV-GLA's utility for elucidating phosphorylation mediated mechanisms and guiding therapeutic discovery. Code and dataset available at https://github.com/ljr078/CMV-GLA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.